Work

P-63 MATTERHORN: A phase 3 study of efficacy and safety of neoadjuvant-adjuvant durvalumab and FLOT chemotherapy in resectable gastric and gastroesophageal junction cancer

Year: 2021

Type: conference-abstract

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2021.05.118

Authors: Y. Janjigian, E. Van Cutsem, K. Muro, Z. Wainberg, S. Al-Batran, W. Hyung, D. Molena, B. Evans, D. Ruscica, S. Robbins, A. Negro, J. Tabernero

Institutions: Memorial Sloan Kettering Cancer Center, Universitair Ziekenhuis Leuven, KU Leuven, Aichi Cancer Center, Aichi Cancer Center Hospital, University of California, Los Angeles, Yonsei University, AstraZeneca (United Kingdom), Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology

Language: English

Topic: Gastric Cancer Management and Outcomes

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: U.S. Department of Defense, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, Bayer Fund, Cycle for Survival, Daiichi-Sankyo, Basilea Pharmaceutica, National Cancer Institute

OpenAlex ID: W3185337775

Cites:

Cited by: 3

Related to: 10